New from #CSO_Scotland https://t.co/wfFTHhLmEy Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
RT @Myeloma_Doc: Updated review of thromboprophylaxis approaches finds low molecular weight heparin superior to warfarin in #myeloma: https…
RT @Myeloma_Doc: Updated review of thromboprophylaxis approaches finds low molecular weight heparin superior to warfarin in #myeloma: https…
Updated review of thromboprophylaxis approaches finds low molecular weight heparin superior to warfarin in #myeloma: https://t.co/H19ok3ACKx
La #prévention des #caillots sanguins chez les patients ... cancer non hospitalisés recevant une #chimiothérapie : https://t.co/jvbkI5bISw
[Cochrane] Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy https://t.co/7emyAKJUai
RT @KFSHRC_Research: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving #chemotherapy https://t.co/GwjR…
RT @KFSHRC_Research: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving #chemotherapy https://t.co/GwjR…
RT @KFSHRC_Research: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving #chemotherapy https://t.co/GwjR…
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving #chemotherapy https://t.co/GwjRq3nQy8 https://t.co/iI2hUJ4EJZ
RT @CochraneLibrary: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients htt…
#CochraneEvidence cannot currently recommend routine prophylaxis for #VTE in ambulatory #chemotherapy patients: https://t.co/3gFaRvG2OU
RT @CochraneUK: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://…
RT @CochraneUK: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://…
RT @aakonc: New systematic review of outpatient thromboprophylaxis. Await ongoing trials for now. https://t.co/HnxkLINR8I
RT @CochraneLibrary: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients htt…
RT @aakonc: New systematic review of outpatient thromboprophylaxis. Await ongoing trials for now. https://t.co/HnxkLINR8I
RT @CochraneUK: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://…
RT @CochraneLibrary: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients htt…
New systematic review of outpatient thromboprophylaxis. Await ongoing trials for now. https://t.co/HnxkLINR8I
RT @CochraneLibrary: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients htt…
RT @CochraneLibrary: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients htt…
More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://t.co/BX7Fuvsc00
RT @CochraneUK: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://…
RT @CochraneUK: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://…
RT @CochraneUK: More evidence needed to assess risks/benefits of routine prophylaxis for #VTE in ambulatory #chemotherapy patients https://…
RT @alfonso_casi: Profilaxis para el tromboembolismo venoso en pacientes ambulatorios con cáncer tratados con quimioterapia, revisión. http…
#VTE reduced by LMWH in ambulatory cancer patients receiving chemo; safety issues re bleeding must be addressed https://t.co/blsVhqQg99
#VTE reduced by LMWH in ambulatory cancer patients receiving chemo; safety issues re bleeding must be addressed https://t.co/blsVhqQg99
RT @FarmaciaOesteAP: (Cochrane) Profilaxis primaria para la TVP en pacientes ambulatorios que reciben quimioterapia https://t.co/TKsVCSRlts
Profilaxis para el tromboembolismo venoso en pacientes ambulatorios con cáncer tratados con quimioterapia, revisión. https://t.co/lItn67NVTP
RT @rincondesisifo: (Cochrane) Profilaxis del TEV en pac oncológicos en tto con quimioterapia https://t.co/IZTmNFLeBR No de rutina
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy @CochraneUK https://t.co/0TtBo95Rfd
Prevention of blood clots in non-hospitalised cancer patients receiving chemotherapy https://t.co/h6evtm84ky
Primary #prophylaxis venous #thromboembolism in ambulatory cancer patients receiving #chemotherapy: https://t.co/yOpTUzFuWM via @Inoreader
RT @FarmaciaOesteAP: (Cochrane) Profilaxis primaria para la TVP en pacientes ambulatorios que reciben quimioterapia https://t.co/TKsVCSRlts
(Cochrane) Profilaxis primaria para la TVP en pacientes ambulatorios que reciben quimioterapia https://t.co/TKsVCSRlts
(Cochrane) Profilaxis del TEV en pac oncológicos en tto con quimioterapia https://t.co/IZTmNFLeBR No de rutina